Stock comparison
Haemonetics
iRhythm Technologies
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
IRTC
iRhythm Technologies
Market cap
$3.83B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | IRTC | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 26F | HAE |
| Benjamin Graham | 85A | 73D | HAE |
| Philip Fisher | 60C | 45D | HAE |
| Peter Lynch | 54C | 70B | IRTC |
| Joel Greenblatt | 31F | 0F | HAE |
| Charlie Munger | 54D | 36D | HAE |
| Terry Smith | 55D | 34F | HAE |
Side-by-side metrics
| Metric | HAE | IRTC |
|---|---|---|
| Market cap | $2.98B | $3.83B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -2.43% |
| Gross margin | 55.74% | 71.0% |
| Net margin | 7.29% | -3.53% |
| Revenue CAGR 5y | 7.65% | 23.34% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 4.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -3.53%+148%
- ROIC (TTM)8.37%vs -2.43%+129%
- Debt / Equity1.5xvs 4.5x+66%
IRTC leads on
- P/E (TTM)-vs 24.8x+119%
- EV/EBIT-vs 14.1x+112%
- Revenue CAGR 5y23.34%vs 7.65%+67%
- Market cap$3.83Bvs $2.98B+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.